Avid Bioservices Inc (CDMO)

[cjgaddy]

11-28-17: Profiles of All 7 BOD Members (+Compensation)
Joseph Carleone (Chairman), Richard Hancock, Gregory Sargen, Joel McComb, Roger Lias, Mark Bamforth, Patrick Walsh



COMPENSATION (6 Non-Employee Directors, see: http://tinyurl.com/y7mvg6wt ):
=> SUMMARY: $55000/yr + $15000/committee + $2000/meeting

STOCK:
FORM4 STOCK OPTIONS AWARDED TO ALL 7 BOD’S: ( http://tinyurl.com/6d4jw8 )
Joseph Carleone (Chairman): 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
Richard Hancock: 75,000 @4.67 vesting monthly over 3yrs beg. 12-27-17
Gregory Sargen: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
Joel McComb: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
Patrick Walsh: 75,000 @4.08, vesting monthly over 3yrs beg. 11-20-17
Mark Bamforth: 75,000 @3.88, vesting monthly over 3yrs beg. 11-17-17
Roger Lias: 150,000 @3.19, vesting in 4 equal annual installments beg. 9-25-18
OPEN MKT PUR:
...Mark Bamforth Buys 50,000sh. @$4.50 (open mkt) on 10-27-17 http://tinyurl.com/ya7pyyu5

NEW DIRECTORS 11-28-17
Joseph Carleone, PhD (CHAIR, “independent of Ronin/SWIM and new to Peregrine”): Dr. Carleone is Chairman of the Board of AMPAC Fine Chemicals LLC, a leading manufacturer of pharmaceutical active ingredients. Prior to this position, Dr. Carleone was President, CEO and director of American Pacific Corp., a leading custom manufacturer of fine and specialty chemicals and propulsion products. Dr. Carleone has also served or currently serves as an officer and/or a director of several directly or indirectly wholly-owned subsidiaries of American Pacific Corp. Dr. Carleone received his bachelor's degree in Mechanical Eng. from Drexel Univ., Philadelphia, Pennsylvania, in 1968; his master's degree in Applied Mechanics from Drexel University in 1970; and his doctorate degree in Applied Mechanics from Drexel Univ. in 1972.

Richard B. Hancock (Ronin/SWIM appointee): Richard (Rick) B. Hancock has worked in the biologic CDMO industry for over 30 years in various operational and executive roles, serving most recently as President and CEO of Althea Technologies, Inc., a large molecule CDMO producing a wide range of biologics, vaccines and parenteral products. In addition to Althea, Mr. Hancock has held senior management positions at The Immune Response Corporation, and Hybritech Inc. (now part of Eli Lilly & Company), and he is currently the Chairman of the Board and Executive Director of Argonaut Manufacturing Services, Inc., a CDMO focused on the biotechnology and life sciences industries. Mr. Hancock received a BA in Microbiology from Miami University.

Joel McComb (Ronin/SWIM appointee): Joel McComb is the CEO, Chairman and Co-Founder of BioSpyder Technologies, Inc. Prior to BioSpyder, Mr. McComb served as Senior Vice President and General Manager of Illumina, Inc., President of GE Healthcare's Life Sciences and Discovery Systems division, and President of GE Healthcare's Interventional Medicine division. Prior to GE Healthcare, Mr. McComb was the President, CEO and a director of Innovadyne Technologies, Inc., and held various positions at Beckman Coulter, Inc., and Charles River Laboratories (at the time a division of Bausch & Lomb Inc.) where he was a National Business Manager for the company's monoclonal antibody CDMO division. Mr. McComb earned a Bachelor of Science degree in Genetics from the Univ. of California, Davis and an MBA from Golden Gate University.

Gregory P. Sargen (Ronin/SWIM appointee): Gregory P. Sargen currently serves as Executive Vice President - Corporate Development and Strategy of Cambrex Corp. (NYSE:CBM) ("Cambrex"), a global manufacturer and provider of services to life sciences companies. Prior to his current role, Mr. Sargen served as Executive Vice President and CFO of Cambrex. Prior to Cambrex, Mr. Sargen served as VP of Finance - Chemicals Manufacturing Div. of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.) (NYSE:TMO), and held positions with Merck & Co., Inc. (NYSE:MRK), Heat and Control, Inc. and Ernst & Young LLP. Mr. Sargen is a Certified Public Accountant (non-practicing) and holds an MBA in Finance from The Wharton School of the Univ. of Pennsylvania and a B.S. in Accounting from Pennsylvania State University.

EXISTING PPHM DIRECTORS PRIOR TO 11-28-17
Patrick D. Walsh (joined 10-24-17): Mr. Walsh currently serves as CEO of Avista Pharma Solutions [https://www.avistapharma.com ], a high-growth CDMO with over 220,000sf of facility space that provides pharmaceutical clients with a full suite of service offerings including analytical, microbiology, API, formulation, drug substance & drug product mfg. expertise & capabilities. Prior to joining Avista Pharma, he was CEO of AAIPharma Services, a private-equity backed CDMO at which he led a successful growth strategy culminating in the company's sale for more than 4.5 times return on invested capital. Mr. Walsh also held the positions of Pres. & COO of Gensia-Sicor, during which time he led the company's commercial growth strategy, culminating in the eventual sale to Teva for $3.4B. Prior to Gensia, he spent 10yrs in a global pharmaceutical company culminating in leading the U.S. and intl. business of a leading Japanese pharma company. Mr. Walsh has served on pharma boards as chairman, non-executive chairman and company director, as well as an executive advisor to private equity & venture capital firms. He currently serves on the board of Avista Pharma, which is backed by private-equity firm Ampersand Capital Partners.
10-24-17 PR: “Mr. Walsh's record of leading successful, high-growth CDMOs is well-documented in the industry and he has also led complex laboratory and pharmaceutical mfg. operations, including parenteral & active pharmaceutical ingredients (API) on a global scale.”

Mark R. Bamforth (joined 10-19-17): Mark R. Bamforth currently serves as Pres./CEO of Brammer Bio, a cell & gene therapy CDMO he founded in 2015 and merged with Florida Biologix, an established, 10yo CDMO, in 3-2016. In this role, he oversees a team of 300+ emps, providing services ranging from process dev. and early clinical supply services to production of Ph3 supplies & support for licensure of gene therapy products. Previously, he founded Gallus BioPharmaceuticals, a biologics CDMO that experienced rapid growth leading to its acquisition by DPx Holdings B.V., the parent company of Patheon, in 2014 for $257.2M.
Prior to his founding of Brammer Bio & Gallus BioPharmaceuticals, Mr. Bamforth spent 22yrs with Genzyme Corp., rising to the position of SVP/Corp.Oper./Pharmaceuticals. In this role, he oversaw a multi-technology, global operations team comprised of 3,600+ at 13 internal sites & a network of 24 CMO’s. This team was charged with supplying 20+ commercial products and multiple clinical products that spanned biologics, cell therapy, gene therapy, pharmaceuticals and biologic devices. While at Genzyme, Mr. Bamforth served as a member of the CEO's operating committee, helping to guide corporate strategy acquisition, partnering and growth to over $4B in sales.
10-19-17/PR/S.King: "Mark is a great addition to the board of directors as we continue our transition to becoming a dedicated CDMO business. With his extensive experience in the CDMO space, both as an entrepreneur who has founded, grown, acquired and sold a successful CDMO company, as well as his experience as a key executive at Genzyme Corp., he is ideally suited to help oversee the transition of the company into a leading CDMO. Combined with the recent appointment of Dr. Roger Lias as Pres. of Avid and member of Peregrine's BOD, today's appointment further underscores our commitment to reconstitute the BOD with high quality CDMO industry experience.”

Roger J. Lias, PhD (joined 9-11-17): Roger J. Lias has held senior mgt. positions at several leading CDMOs including Cytovance Biologics, KBI BioPharma, Diosynth RTP (formerly Covance Biotechnology Services) and Lonza Biologics. At each of these companies, he was primarily charged with overseeing commercial operations, including growing and diversifying their respective client bases. During this time, Dr. Lias' achievements ranged from building start-up Cytovance's contract process development and biopharmaceutical cGMP production business, to increasing revenues at Diosynth from $16 million to $120 million over a four-year period. Additionally, he has built a reputation as a highly regarded CDMO industry advocate who has contributed to the acceptance and growth of the biologics contract manufacturing market. Dr. Lias earned his Ph.D. from Clare College at the Univ. of Cambridge in the United Kingdom. Dr. Lias most recently served as executive director, head of global biologics business development for Allergan plc., where he was responsible for developing and executing strategies designed to support the company's business development activities related to innovative biologics, biosimilars and complex injectable products. In this role, he was instrumental in identifying, structuring and negotiating a biosimilars co-development collaboration with Amgen for four oncology biosimilar monoclonal antibody products. Prior to Allergan, Dr. Lias was president and group commercial director for Eden Biodesign, an established biopharmaceutical contract manufacturer and consultancy and wholly-owned subsidiary of Eden Biopharma Group. During his time with Eden Biodesign, he successfully transitioned the company's CDMO client base from early-stage biotechnology companies to established biotechnology and multinational pharmaceutical companies, while also playing a key role in the eventual sale of Eden Biopharma Group to Watson Pharmaceuticals (now Allergan).
9-11-17/PR/S.King: “We are very pleased to have the opportunity to bring someone with Roger's impressive track record within the CDMO industry to help guide expansion and growth of the business. Roger has a solid track record of success in driving business expansion, growing revenues and building stockholder value. We are looking forward to seeing the positive impact Roger can have on the Avid business and I look forward to closely working with him to maintain the continuity of the business during the coming transition."

= = = = = = = = = = = = = = = = = = = =
11-28-17: FULL HISTORY of PPHM-Ronin PR’s, Letters, 13-D’s, Form4’s, Proxy’s, etc: https://tinyurl.com/y7g72zh4

KNOWN UPCOMING:
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
Jan18: Peregrine's 2017 Annual Shareholder’s Meeting – 11-13-17/PR: http://tinyurl.com/y9tdcob5 VotingRecDate: 11-27-17